- Home
- RQI vs ANAB Comparison
RQI vs ANAB Comparison
Compare RQI & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RQI | ANAB |
|---|---|---|
| Founded | 2002 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | RQI | ANAB |
|---|---|---|
| Price | $11.62 | $43.56 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $59.90 |
| AVG Volume (30 Days) | ★ 432.6K | 413.9K |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 8.20% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $169,467,000.00 |
| Revenue This Year | N/A | $135.45 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 196.42 |
| 52 Week Low | $9.17 | $12.21 |
| 52 Week High | $12.64 | $52.47 |
Technical Indicators
Market Signals| Indicator | RQI | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 51.11 | 44.47 |
| Support Level | $11.37 | $46.89 |
| Resistance Level | $11.60 | $52.47 |
| Average True Range (ATR) | 0.11 | 2.27 |
| MACD | 0.02 | -0.80 |
| Stochastic Oscillator | 91.91 | 7.62 |
Price Performance
Historical ComparisonAbout RQI Cohen & Steers Quality Income Realty Fund Inc
COHEN & STEERS QUALITY INCOME REALTY FUND INC is a diversified, closed-end management investment company. The primary investment objective of the fund is high current income through investment in real estate securities. Its secondary objective is capital appreciation. The Fund invests at least its total assets in income-producing common stocks and other securities issued by real estate companies, such as real estate investment trusts under normal market conditions.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).